login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
MANNKIND CORP (MNKD) Stock News
USA
- NASDAQ:MNKD -
US56400P7069
-
Common Stock
5.59
USD
+0.04 (+0.72%)
Last: 10/31/2025, 2:01:05 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MNKD Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Zacks Investment Research
- Mentions:
PTGX
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?
2 days ago - By: MannKind
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
2 days ago - By: MannKind
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
18 days ago - By: MannKind
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
18 days ago - By: MannKind
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
2 months ago - By: Stocktwits
- Mentions:
UTHR
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
24 days ago - By: MannKind
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
24 days ago - By: MannKind
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
a month ago - By: MannKind
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
a month ago - By: MannKind
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
2 months ago - By: Stocktwits
- Mentions:
UTHR
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together
2 months ago - By: Zacks Investment Research
- Mentions:
CVGI
INBK
New Strong Sell Stocks for August 27th
3 months ago - By: Stocktwits
- Mentions:
BX
MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’
2 months ago - By: Zacks Investment Research
- Mentions:
DNLI
Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?
2 months ago - By: Benzinga
- Mentions:
INSM
CNC
MOH
UNH
...
10 Health Care Stocks Whale Activity In Today's Session
2 months ago - By: Benzinga
- Mentions:
SBSW
ULCC
CIFR
APO
...
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
2 months ago - By: Yahoo Finance
MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza
2 months ago - By: Brodsky & Smith LLC
- Mentions:
SCPH
VTLE
IMXI
HBI
...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)
2 months ago - By: MannKind
MannKind to Present at Upcoming Investor Conferences
2 months ago - By: MannKind
MannKind to Present at Upcoming Investor Conferences
2 months ago - By: MannKind
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
2 months ago - By: MannKind
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
2 months ago - By: Stocktwits
- Mentions:
SCPH
MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish
2 months ago - By: Stocktwits
- Mentions:
SCPH
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside
2 months ago - By: MannKind
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
2 months ago - By: MannKind
- Mentions:
SCPH
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
2 months ago - By: Yahoo Finance
Leerink Partners Reiterates a Buy on MannKind Corporation (MNKD), Keeps the PT
2 months ago - By: Yahoo Finance
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
3 months ago - By: The Motley Fool
MannKind (MNKD) Q2 Revenue Rises 6%
3 months ago - By: Zacks Investment Research
MannKind (MNKD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
PHAT
MannKind (MNKD) Reports Break-Even Earnings for Q2
3 months ago - By: MannKind
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
3 months ago - By: MannKind
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
Please enable JavaScript to continue using this application.